International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)

Abstract Background Real-world data on non-vitamin K oral anticoagulants (NOACs) are essential in determining whether evidence from randomised controlled clinical trials translate into meaningful clinical benefits for patients in everyday practice. RIVER (RIVaroxaban Evaluation in Real life setting)...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Jan Beyer-Westendorf, A. John Camm, Keith A. A. Fox, Jean-Yves Le Heuzey, Sylvia Haas, Alexander G. G. Turpie, Saverio Virdone, Ajay K. Kakkar, for the RIVER Registry Investigators
Médium: Artigo
Jazyk:Inglês
Vydáno: BMC 2019-04-01
Edice:Thrombosis Journal
Témata:
Anticoagulant
Antithrombotic
Atrial fibrillation
Outcomes
Registry
Rivaroxaban
On-line přístup:http://link.springer.com/article/10.1186/s12959-019-0195-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky